Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

EverSea Medicines to acquire Hasten Biopharmaceuticals

 April 9, 2026

Pharmaceutical Business Review

The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets.

M&A / DealsRead full story

Post navigation

Jeito Capital secures over $1.2bn for new biopharma investments →
← 23andMe study explains variable results with obesity drugs

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com